Plasma markers and breast cancer risk & treatment
Part of Cancer, Skin clinical trials.
This study looks at substances in your blood (metabolites) to see if they are linked to breast cancer risk, how well treatment works, and long-term outcomes. It has three groups: women without breast cancer, newly diagnosed patients getting standard therapy, and those who have finished treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Must be an adult woman (implied by context of breast cancer study).
- For the main study groups: either newly diagnosed with breast cancer and no prior treatment, or have completed breast cancer treatment, or are a woman without cancer.
- Must not have breast cancer that has spread to distant parts of the body.
- Must not have another type of cancer besides breast cancer.
- Must not have joined another clinical trial (except observational ones) in the past month.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how age-related changes in your blood might affect how well your breast cancer treatment works. It includes people with hormone receptor-positive, HER2-negative breast cancer that has not spread to distant organs.
This study examines tiny particles in your blood from breast cancer cells to better predict which treatments will work best for you. Researchers will collect blood samples and a small tissue sample to understand your cancer's characteristics and help doctors choose more effective therapy.
This trial uses a special blood test to track cancer signals (called ctDNA) during and after treatment for early breast cancer. It aims to see whether monitoring these signals can help guide follow-up and treatment decisions.
This trial checks whether specific “surveillance” markers (measured from blood and bone marrow) can help predict if breast cancer comes back after standard treatments. It may help doctors monitor you more accurately and earlier if recurrence risk is high.
This study looks at proteins and imaging patterns (from tissue, fluid near the tumor, and blood) to better understand breast cancer markers. It may help researchers find clues that doctors can use to evaluate breast nodules and newly diagnosed invasive breast cancer.
This study looks at breast cancer samples taken by biopsy to see how tissue “molecular markers” relate to how you respond to therapy and how the cancer behaves. It may help researchers better match future treatments to the biology of your tumor.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.